États-Unis · Agences & temps réel · PR Newswire

Johnson & Johnson reports 75% tumor response rate in advanced prostate cancer with JNJ-6143, a first-in-class RIPTAC™ molecule

Publié par PR Newswire · États-Unis il y a 1 h

JNJ-6143 is an investigational, once-daily, novel, small molecule designed to trigger cancer cell death through a targeted dual-protein lock between BRD4 and androgen receptor, a…

Lire l'article complet sur PR Newswire Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.prnewswire.com)

Johnson & Johnson reports 75% tumor response rate in advanced prostate cancer with JNJ-6143, a first-in-class RIPTAC™ molecule

À lire aussi

Semtech Brings 5G Network Slicing, FIPS 140-3 to IACP 2026

Brazil’s Lula opens state toolbox to woo voters in runoff against Bolsonaro. Here’s what is on offer

Dragonfly On-demand Webinar: Middle East: Anticipating a convergence of conflicts

MT Newswires' MCP Server Now Available in Perplexity Computer, Bringing Real-Time Global Market News to AI-Driven Workflows

Johnson & Johnson reports 75% tumor response rate in advanced prostate cancer with JNJ-6143, a first-in-class RIPTAC™ molecule

Partager

À lire aussi

Semtech Brings 5G Network Slicing, FIPS 140-3 to IACP 2026

Brazil’s Lula opens state toolbox to woo voters in runoff against Bolsonaro. Here’s what is on offer

Dragonfly On-demand Webinar: Middle East: Anticipating a convergence of conflicts

MT Newswires' MCP Server Now Available in Perplexity Computer, Bringing Real-Time Global Market News to AI-Driven Workflows